Bp Plc Buys Shares of 28,137 Esperion Therapeutics Inc (ESPR)

Bp Plc bought a new position in Esperion Therapeutics Inc (NASDAQ:ESPR) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 28,137 shares of the biopharmaceutical company’s stock, valued at approximately $1,130,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Advisor Group Inc. lifted its stake in shares of Esperion Therapeutics by 44.4% in the 4th quarter. Advisor Group Inc. now owns 947 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 291 shares during the period. Parallel Advisors LLC acquired a new stake in shares of Esperion Therapeutics in the 1st quarter worth $80,000. Rehmann Capital Advisory Group acquired a new stake in shares of Esperion Therapeutics in the 4th quarter worth $97,000. Xact Kapitalforvaltning AB acquired a new stake in shares of Esperion Therapeutics in the 4th quarter worth $200,000. Finally, SG Americas Securities LLC purchased a new position in shares of Esperion Therapeutics in the 4th quarter valued at about $203,000.

Shares of ESPR opened at $51.57 on Wednesday. The stock has a market capitalization of $1.39 billion, a PE ratio of -6.84 and a beta of 2.11. Esperion Therapeutics Inc has a 52-week low of $35.80 and a 52-week high of $60.99.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported $3.07 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.64 by $2.43. The company had revenue of $145.42 million during the quarter, compared to analysts’ expectations of $69.35 million. During the same quarter in the prior year, the business earned ($1.73) EPS. As a group, analysts forecast that Esperion Therapeutics Inc will post -2.09 earnings per share for the current fiscal year.

In other Esperion Therapeutics news, Director Roger S. Newton sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $50.06, for a total transaction of $1,251,500.00. Following the completion of the transaction, the director now directly owns 548,726 shares in the company, valued at approximately $27,469,223.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Timothy M. Mayleben bought 5,000 shares of the company’s stock in a transaction on Thursday, March 14th. The shares were acquired at an average price of $48.73 per share, with a total value of $243,650.00. Following the completion of the acquisition, the chief executive officer now directly owns 51,163 shares in the company, valued at approximately $2,493,172.99. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 65,000 shares of company stock valued at $3,155,550 and have sold 48,329 shares valued at $2,280,206. Company insiders own 7.70% of the company’s stock.

A number of equities analysts have recently issued reports on ESPR shares. Bank of America upgraded shares of Esperion Therapeutics from an “underperform” rating to a “neutral” rating in a report on Monday, May 6th. Zacks Investment Research downgraded shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, February 8th. Northland Securities reiterated a “buy” rating and issued a $65.00 price target on shares of Esperion Therapeutics in a report on Friday, March 1st. JPMorgan Chase & Co. upgraded shares of Esperion Therapeutics from an “underweight” rating to a “neutral” rating and increased their price target for the company from $38.00 to $47.00 in a report on Wednesday, March 13th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $112.00 price target on shares of Esperion Therapeutics in a report on Friday, March 29th. One research analyst has rated the stock with a sell rating, four have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Esperion Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $75.45.

TRADEMARK VIOLATION WARNING: This report was reported by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.baseballdailydigest.com/news/2019/05/22/bp-plc-buys-shares-of-28137-esperion-therapeutics-inc-espr.html.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Recommended Story: Cost of Capital

Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics Inc (NASDAQ:ESPR).

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.